Monoclonal antibody · Immune activation, directed at LAG3 and PD-1 (PDCD1) · developed by Merck &
Favezelimab/pembrolizumab is a coformulation of two humanized IgG4 monoclonal antibodies: favezelimab, which binds LAG3 on tumor-infiltrating lymphocytes and blocks its interaction with MHC class II, and pembrolizumab, which binds PD-1 and blocks its activation by PD-L1 and PD-L2. It is studied in solid tumors and hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
Hematologic MalignanciesSolid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.
See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MRK catalysts and pipeline →